While our HIV and hepatitis drugs are significant revenue contributors to Gilead, additional products continue to generate revenue and extend our corporate brand as proven treatments for a range of other infectious and viral diseases. AmBisome, Tamiflu and Vistide collectively delivered solid financial results during 2006.
of all common strains of influenza A and B and is available in pill and liquid suspension form. Last flu season, doctors wrote more prescriptions for Tamiflu than any other antiviral flu treatment. Tamiflu has also demonstrated effectiveness in blocking replication of the H5N1 virus, which is known to cause avian flu. To date, 75 countries have begun to stockpile Tamiflu in the event of an influenza pandemic.
VISTIDE
Marketed in the United States by Gilead and internationally by Pfizer Inc., Vistide is an antiviral for the treatment of cytomegalovirus retinitis in AIDS patients. The year 2006 marked the 10th anniversary of the product’s initial launch.
AMBISOME
First approved in Europe more than 15 years ago, AmBisome remains a strong seller even in the face of new competition. AmBisome is used to treat systemic fungal infections, particularly in immunocompromised patients. These fungal infections are increasingly common in hospital settings. Astellas Pharma Inc. promotes and sells AmBisome in the United States and Canada. Dainippon Sumitomo Pharma Co., Ltd. markets AmBisome in Japan. Gilead retains exclusive marketing rights to AmBisome throughout the rest of the world. AmBisome is available in more than 40 countries worldwide.
TAMIFLU
Discovered by Gilead and marketed worldwide by Roche, Tamiflu is approved for the treatment and prevention
